ChromaDex to Present at the 30th Annual ROTH Conference on March 12, 2018
March 06 2018 - 5:30AM
ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated
nutraceutical company devoted to pioneering technologies that
improve the way people age, has been invited to present at the 30th
Annual ROTH Capital Partners Conference. The conference is being
held on March 11-14, 2018 at The Ritz-Carlton in Dana Point, Calif.
ChromaDex management is scheduled to present on Monday, March
12th at 7:30 a.m. Pacific time, with one-on-one meetings held
throughout the day.
For more information about the conference or to schedule a
one-on-one meeting with ChromaDex management, please contact your
ROTH representative or the Company’s investor relations team at
949-574-3860.
About ChromaDex:
ChromaDex Corp. is an integrated, global nutraceutical company
devoted to improving the way people age. ChromaDex scientists
partner with leading universities and research institutions
worldwide to uncover the full potential of NAD and identify and
develop novel, science-based ingredients. Its flagship ingredient,
NIAGEN® nicotinamide riboside, sold directly to consumers as TRU
NIAGEN®, is backed with clinical and scientific research, as well
as extensive IP protection. TRU NIAGEN® is helping the world AGE
BETTER®. To learn more about ChromaDex, please visit
www.ChromaDex.com.
Forward-Looking Statements:
This release contains forward-looking statements relating to
ChromaDex and ChromaDex’s business within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities and Exchange Act of 1934, as amended, including
statements related to the results of the recently published study
and whether it is further confirmation as to the benefits of
NIAGEN®. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2016, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof. Embroider
ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288andrewj@chromadex.com
ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
949-537-4103breaho@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2024 to May 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From May 2023 to May 2024